<DOC>
	<DOCNO>NCT01404910</DOCNO>
	<brief_summary>Preeclampsia syndrome occur approximately 3 % 8 % pregnancy associate considerable maternal neonatal morbidity mortality . Except termination pregnancy , effective treatments/preventative measure preeclampsia lack . Although prolongation pregnancy benefit fetus , detrimental mother , associate hypertension , proteinuria , symptom suggest kidney , brain , liver cardiovascular system involvement . Placental soluble fms-like tyrosine kinase 1 ( sFlt-1 ) elevate woman preeclampsia , level fall delivery . sFlt-1 variant vascular endothelial growth factor ( VEGF ) receptor Flt-1 , circulation , act potent VEGF placental growth factor ( PlGF ) antagonist . Given sFlt-1 level elevate preeclampsia , investigate removal sFlt-1 plasma woman preeclampsia improve maternal fetal outcome . Short-term extracorporeal apheresis LIPOSORBER LA-15 System primary intervention use method previously apply pregnant woman familial hypercholesterolemia .</brief_summary>
	<brief_title>Removal Anti-Angiogenic Proteins Preeclampsia Before Delivery</brief_title>
	<detailed_description>The primary objective trial determine whether short-term apheresis use dextran sulfate adsorption ( DSA ) column ( Liposorber LA-15 System ; Device ) lead reduction circulate sFLT-1 blood woman pre-term preeclampsia . The following secondary objective aim evaluate efficacy safety Device well impact remove circulate sFlt-1 maternal neonatal outcome : 1 . To determine whether short-term apheresis use Device woman pre-term preeclampsia lead : - prolongation pregnancy ( ie , gestational age ) - reduction blood pressure ( BP ) proteinuria - increase fetal birth weight 2 . To determine safety reduce maternal sFlt-1 level use Device . Up 16 patient enrol . Initially , 4 patient undergo apheresis UP TO 2 time first week undergo protocol-related assessment include PK sFlt-1 level . Based assessment clinical response Investigator , first 4 patient offer option continue apheresis treatment ( without pharmacokinetic [ PK ] assessment ) twice weekly delivery 34 week gestation , whichever come first . Following complete review parameter outcomes independent Data Safety Monitoring Board ( DSMB ) , 12 additional patient enrol ( total 16 ) . UPDATE : The DSMB review data first 4 patient 10 patients/delivered infant treat . In next 6 patient , DSMB review occur every 3 patients/delivered infant . These remain 6 patient may undergo apheresis 3 time per week .</detailed_description>
	<mesh_term>Pre-Eclampsia</mesh_term>
	<mesh_term>Dextrans</mesh_term>
	<criteria>Inclusion Criteria ( maternal ) : 1 . Signed informed consent pregnant woman age 18 45 year hospitalized preterm preeclampsia 2 . Preterm preeclampsia define systolic BP ≥140 mm Hg ≥90 mm Hg diastolic 23 week gestation 32 week gestation woman previously normal BP proteinuria 0.3 gram 24hour specimen urine protein/creatinine ratio &gt; 0.30 . 3. sFlt1/PlGF ratio &gt; 85 ( blood level sFlt1 PlGF determine use CEapproved Roche Diagnostics assay ) . Exclusion Criteria ( Maternal Fetal ) : Maternal : 1 . Taking form angiotensin cascade blocker 2 . History diagnosis preexist chronic hypertension ( first 3 patient ) 3 . History cardiac impairment include uncontrolled arrhythmia , unstable angina , decompensated congestive heart failure valvular disease 4 . History diagnosis chronic renal disease 5 . Patients receive anticoagulation therapy prior study entry 6 . Anticipated immediate delivery within 24 hour 7 . Signs central nervous system ( CNS ) dysfunction , include seizure , cerebral edema ( CTscan MRI ) 8 . History thyroid disease 9 . History liver abnormalities 10 . Pulmonary edema 11 . Thrombocytopenia ( platelet count &lt; 100,000/mm3 ) 12 . Anemia hemoglobin &lt; 8 g/dL 13 . Evidence `` reverse Doppler '' flow umbilical Doppler 14 . Placenta previa 15 . Placental abruption 16 . Preterm labor 17 . Active hepatitis B , C , tuberculosis infection HIV positive status 18 . Any condition investigator deem risk patient fetus complete study . 19 . Any condition opinion investigator would necessitate delivery next 24 hour Fetal characteristic would exclude mother participate : 1 . Trisomy 2 . Biophysical profile ( BPP ) &lt; 6 3 . Amniotic fluid index ( AFI ) &lt; 5 cm 4 . Estimated fetal weight ( EFW ) &lt; 5th percentile gestational age ( IUGR )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pregnancy</keyword>
	<keyword>Preeclampsia</keyword>
	<keyword>Pre-term</keyword>
	<keyword>sFlt-1</keyword>
	<keyword>Apheresis</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Proteinuria</keyword>
	<keyword>VEGF</keyword>
</DOC>